| |
CEBAM
|
ACP
|
HAS
|
KDIGO
|
KHA-CARI
|
BCMA
|
UMHS
|
VA-DoD
|
NICE
|
|---|
|
2012
|
2013
|
2013
|
2013
|
2013
|
2014
|
2014
|
2014
|
2015
|
|---|
|
Management of anemia
|
|
diagnosis
|
definition
|
▪
| | |
▪
| | |
▪
| |
▪
|
| |
lower limit in g/dl
|
11
| | |
M: 13, F: 12
| | |
M: 13, F: 12
| |
11
|
|
monitoring
|
monitor for anemia
|
▪
| |
▪
|
▪
| |
i
|
▪
| | |
| |
tests
|
▪
| | |
▪
| | |
▪
| | |
| |
frequency (per year)
|
individual
| | |
1–4
| | | | | |
|
initial evaluation
| | | | | | | |
▪
| | |
|
treatment options
|
iron
|
▪
| |
i
| | | | |
▪
| |
| |
erythropoetin
|
▪
| |
i
| | | | | | |
| |
nutritional supplements
| | |
i
| | | | | | |
| |
androgens
| | | | | | | | | |
| |
blood transfusion
| | |
−/i*
| | | | | | |
|
treatment
|
indications
| | |
▪
| | | | | | |
| |
target values
| | |
▪
| | | | | | |
| |
monitoring
| | |
▪
| | | | | | |
| |
erythropoietine resistance
| | |
▪
| | | | | | |
| |
referral
| | |
▪
| | | | | | |
- ▪ recommendation, − negative recommendation, F: female, M: male, i: when indicated, *Transfusions should be avoided (risk of allo-immunization). The only indications are symptomatic anemia in patients with an associated risk factor; acute worsening of anemia by blood loss (hemorrhage, surgery), hemolysis or resistance to erythropoietin. A search for anti-HLA antibodies should be performed before and after any transfusion in patients waiting for kidney transplant
- American College of Physicians (ACP), Belgisch Centrum voor Evidence Based Medicine (CEBAM), British Columbia Medical Association (BCMA), Department of Veteran’s Affairs (VA-DoD), Haute Autorité de Santé (HAS), Kidney Disease Improving Global Outcomes (KDIGO), Kidney Health Australia - Caring for Australasiansians with Renal Impairment (KHA-CARI), National Institute of Health and Care Excellence (NICE), University of Michigan Health System (UMHS)
